Loading...
01/09 23:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a strong financial position with significant investments from AstraZeneca and stable cash reserves. The Q&A section highlights confidence in upcoming data releases, suggesting positive future developments. The collaboration with AstraZeneca is fully reimbursed, reducing cash burn. Despite competitive pressures and supply chain challenges, the overall sentiment leans positive due to strategic partnerships and financial strength.
Equity Investment from AstraZeneca $140 million investment from AstraZeneca, which is a new addition compared to the previous year.
Cash Position $264 million as of December 31, 2024, an increase of $108 million from $156 million as of December 31, 2023, primarily due to the $140 million from AstraZeneca and $20 million from the European Investment Bank.
Revenue from Collaboration $47 million received under the joint research and collaboration agreement with AstraZeneca, which includes $25 million upfront and $22 million from development milestones.
Consolidated Net Loss Details on consolidated net loss attributable to shareholders for the 12-months ended December 31, 2024, were mentioned but not specified in the transcript.
Cash Payments $47 million paid to suppliers, $40 million for wages, bonuses, and social expenses, $11 million for lease debts, and $5 million for repayment of the PGE loan.
New Product Development: Cellectis announced the start of research and development activities for three programs under collaboration with AstraZeneca, including an allogeneic CAR T for hematological malignancies, an allogeneic CAR T for solid tumors, and an in vivo gene therapy for a genetic disorder.
Clinical Trials: Cellectis plans to present Phase 1 data for UCART22 in the third quarter of 2025 and is focusing on the BALLI-01 and NATHALI-01 studies.
Market Expansion: AstraZeneca completed an additional equity investment of $140 million, increasing their ownership to approximately 44% of Cellectis.
Cash Position: Cellectis reported cash and equivalents of $264 million as of December 31, 2024, up from $156 million in 2023, sufficient to fund operations into mid-2027.
Operational Efficiency: Cellectis is focusing on developing UCART22 and UCART20x22 while managing R&D pipeline and controlling SG&A expenses.
Strategic Collaboration: Cellectis is excited about the strategic collaboration with AstraZeneca, which is expected to shape the future of cell and gene therapies.
Financial Risks: Cellectis faces financial risks related to the sufficiency of cash to fund operations, despite current confidence in cash runway extending to mid-2027.
Regulatory Risks: There are regulatory risks associated with the development of clinical programs, including the need for alignment with FDA and EMA on Phase 2 registration strategies.
Competitive Pressures: Cellectis operates in a highly competitive environment in the cell and gene therapy market, which may impact its market position and financial performance.
Supply Chain Challenges: The company may encounter supply chain challenges that could affect the manufacturing and delivery of its therapies.
Economic Factors: Economic factors, including fluctuations in funding and investment climate, could impact Cellectis's financial stability and growth prospects.
Collaboration with AstraZeneca: Cellectis announced the start of research and development activities for three programs under collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies and solid tumors, and an in vivo gene therapy for a genetic disorder.
Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis, acquiring 10 million Class A and 18 million Class B convertible preferred shares.
Cash Runway: Cellectis' cash runway is projected to fund operations into mid-2027, supported by financing activities and partnerships.
Clinical Trials Focus: Cellectis will focus on advancing core clinical trials, particularly BALLI-01 and NATHALI-01, while building the next generation of genomic medicines.
Phase 1 Data Presentation: Cellectis expects to present Phase 1 data set and late-stage development strategy for UCART22 in Q3 2025.
Phase 2 Study Preparation: Cellectis plans to open recruitment for a Phase 2 study in Q4 2025 for UCART22.
Financial Position: Cellectis reported cash and equivalents of $264 million as of December 31, 2024, an increase from $156 million in 2023, indicating a strong financial position.
Future Revenue Expectations: Cellectis anticipates continued revenue from collaboration with AstraZeneca, with $47 million received under the joint research agreement by year-end 2024.
AstraZeneca Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis, subscribing for 10 million Class A convertible preferred shares and 18 million Class B convertible preferred shares at a price of $5 per share.
Cash Position: Cellectis reported cash, cash equivalents, restricted cash, and fixed term deposits of $264 million as of December 31, 2024, an increase of $108 million from the previous year.
Funding from EIB: Cellectis drew down the second tranche of €15 million and the third tranche of €5 million under a credit facility agreement with the European Investment Bank.
Research Collaboration Payments: Cellectis received $47 million under the joint research and collaboration agreement with AstraZeneca, including $25 million upfront and $22 million for development milestones.
The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.
The earnings call reveals a strong financial position with significant investments from AstraZeneca and stable cash reserves. The Q&A section highlights confidence in upcoming data releases, suggesting positive future developments. The collaboration with AstraZeneca is fully reimbursed, reducing cash burn. Despite competitive pressures and supply chain challenges, the overall sentiment leans positive due to strategic partnerships and financial strength.
The earnings call presents mixed signals. The AstraZeneca collaboration and strong cash position are positive indicators, but supply chain challenges and intense competition in cell and gene therapy pose risks. The Q&A reveals management's cautious approach to prioritizing projects and lack of clarity on future datasets. Additionally, deprioritizing UCART123 raises concerns. Despite these issues, the partnership with AstraZeneca provides a financial buffer, mitigating some negative impacts. Overall, the sentiment is neutral as positives balance out the negatives.
The earnings call reveals strong financial improvement, with a significant turnaround from a loss to a profit, which is a positive indicator. The collaboration with AstraZeneca and the potential for new programs provide further optimism. The Q&A section highlights ongoing developments and market expansion potential, especially in the EU. Although management avoided some specifics, the overall sentiment remains positive due to the financial recovery and strategic partnerships.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
